Navigation Links
Inverness Medical Innovations Announces Third Quarter 2008 Results
Date:10/29/2008

59,552) 155,349

Operating income (loss) 13,247 72,273 85,520

Interest and other income

(expense), net (24,752) 300( c ) (24,452)

Income tax (benefit)

provision (4,696) 26,018(g) 21,322

Equity earnings of

unconsolidated entities,

net of tax 3,150 237(b) 3,387

Net (loss) income $(3,659) $46,792 $43,133

Preferred stock dividends $(5,393) $(5,393)

Net (loss) income

available to common

stockholders - basic $(9,052) $37,740

Net (loss) income per

common share

Basic $(0.12) $0.48

Diluted $(0.12)(h) $0.46(i)

Weighted average common

shares - basic 77,995 77,995

Weighted average common

shares - diluted 77,995(h) 83,169(i)

Three Months Ended September 30, 2007

Non-GAAP

Non-GAAP Adjusted Cash

GAAP Adjustments Basis(a)

Net revenue $237,636 $- $237,636

Cost of revenue 127,338 (13,938)(b)(d)(e) 113,400

Gross profit 110,298 13,938 124,236

Gross margin 46% 52%

Operating expenses:

Research and development 20,530 (1,535)(b)( c )(d) 18,995

Purchase of in-process

research and development 169,000 (169,000)(f) -

Selling, ge
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 29, 2008 to Discuss Third Quarter 2008 Results
2. Inverness Medical Innovations to Present at the UBS Global Life Sciences Conference on September 22, 2008
3. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
4. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
5. Inverness Medical Innovations to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008
6. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
7. Inverness Medical Innovations to Present at Canaccord Adams 28th Annual Growth Conference on August 12, 2008
8. Inverness Medical Innovations Announces Second Quarter 2008 Results
9. Inverness Medical Innovations to Present at Jefferies 2nd Annual Healthcare Conference held on June 25, 2008
10. Inverness Medical Innovations to Present at 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on June 12, 2008
11. Inverness Medical Innovations to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 28, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... CITY, Calif. , March 4, 2015 /PRNewswire/ ... ), a specialty pharmaceutical company focused on the ... treatment of acute and breakthrough pain, today announced ... 2014 financial results after market close on Monday, ... investment-community conference call at 4:30 p.m. Eastern Time ...
(Date:3/4/2015)... San Jose, California (PRWEB) March 04, 2015 ... Chain Reaction (PCR) represents one of the fastest growing ... among cell biologists in subcellular visualization is driving growth ... The need for deeper understanding of gene expressions will ... reagents market. Expanding applications in fields ranging from pharma, ...
(Date:3/4/2015)... ANDOVER, Massachusetts , March 4, 2015 /PRNewswire/ ... Unternehmen präsentiert innovative Entwicklungen für Diagnostik und Therapie, ... Gesundheitsversorgung   Royal Philips ... am Europäischen Röntgenkongress 2015 (ECR) bekannt, ... stattfindet. An den Ständen Nr. ...
(Date:3/3/2015)... 3, 2015 NASA astronaut Scott Kelly , ... to spend a year living and working on the International ... 5:30 to 7 a.m. EDT Monday, March 9. ... he completes the final weeks of his training. The interviews ... NASA Television highlighting his mission training and previous spaceflights. ...
Breaking Biology Technology:AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... , NEW YORK , ... (OTC Bulletin Board: ILNS), a biopharmaceutical company focused ... ("AD"), announced today that several of its significant shareholders ... interim funding to the Company and assist the Company ...
... SILVER SPRING, Md. , and INDIANAPOLIS , Feb. ... United Therapeutics Corporation (Nasdaq: UTHR ), announced today that ... to pursue development of ImmuneWorks, lead compound, IW001, a purified ... Idiopathic Pulmonary Fibrosis (IPF) and Primary Graft Dysfunction (PGD) in ...
... , , NEW YORK , ... Vice President James C. Borel said he expects the ... in 2010 and increase pre-tax operating income margin across the seed, ... on customers and investing to meet their needs is paying off," ...
Cached Biology Technology:Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 2Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 3Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 4Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 2Lung Rx and ImmuneWorks Announce Collaboration in Idiopathic Pulmonary Fibrosis and Primary Graft Dysfunction 3DuPont Expects Strong 2010 Agriculture & Nutrition Sales Growth, Margin Expansion 2DuPont Expects Strong 2010 Agriculture & Nutrition Sales Growth, Margin Expansion 3DuPont Expects Strong 2010 Agriculture & Nutrition Sales Growth, Margin Expansion 4DuPont Expects Strong 2010 Agriculture & Nutrition Sales Growth, Margin Expansion 5
(Date:3/2/2015)... March 2, 2015   Neurotechnology , a provider ... the SentiGaze Software Development Kit (SDK). The ... that use off-the-shelf webcams to track eye movements and ... a monitor. Heatmaps can be used for applications such ... online advertising. The SDK can also be used to ...
(Date:2/24/2015)... 2015 Research and Markets ( ... "Global 2D Gesture Recognition Market 2015-2019" ... analysts forecast the Global 2D Gesture Recognition market ... the period 2014-2019 The increased demand ... one of the major trends in the market. ...
(Date:2/13/2015)... ACT Genomics Co., Ltd., a cancer ... cancer genomic information into precision diagnosis and personalized ... US$ 8 million in the its first private funding ... Taiwan , ACT Genomics has developed comprehensive ... to implement next generation sequencing (NGS) and multiplex ...
Breaking Biology News(10 mins):Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2
... million grant from the National Science Foundation to lead ... agricultural crop plants able to withstand drought conditions. The ... plant ( Brassica napus ). Canola is an important ... production. June Kwak, associate professor of cell biology and ...
... AVIV, Israel - European business leaders and high-level representatives ... entrepreneurs and industries, will gather in Tel Aviv during ... the first event in Israel under the Israeli EUREKA ... of the EUREKA Network and will provide European industries ...
... HILL, Mass. (10/25/2010) The development and first use ... mosquito have established 400,000 genetic markers capable of revealing ... insecticides and other preventive measures, according to findings published ... . The SNP array,s snapshot of the Anopheles ...
Cached Biology News:UMD to lead $5 million NSF-funded research partnership to develop drought-tolerant canola crops 2UMD to lead $5 million NSF-funded research partnership to develop drought-tolerant canola crops 3Israeli Minister of Industry and Trade to address European R&D leaders in Tel Aviv 2Genetic markers offer new clues about how malaria mosquitoes evade eradication 2Genetic markers offer new clues about how malaria mosquitoes evade eradication 3
... of long double stranded RNA (dsRNA) has ... a diverse group of organisms as well ... leads to the inhibition of protein expression ... target messenger RNA (mRNA). Attempts to induce ...
... in an easy-to-use benchtop package. Our ... (ESI-oa-TOF) concentrates the performance of a ... fits on your bench. The microTOFLC ... FWHM and mass accuracy of better ...
... Definitive Performance The TSQ Quantum ... excellence in bioanalytical and environmental analysis. ... ESI and APCI probes, a titanium skimmer ... increased robustness and sensitivity. Its redesigned ...
... uptake of long double stranded RNA (dsRNA) ... in a diverse group of organisms as ... interference leads to the inhibition of protein ... the target messenger RNA (mRNA). Attempts to ...
Biology Products: